Full metadata record
DC FieldValueLanguage
dc.creatorLahuerta, J.J. (Juan José)-
dc.creatorPaiva, B. (Bruno)-
dc.creatorVidriales, M.B. (María Belén)-
dc.creatorCordón, L. (Lourdes)-
dc.creatorCedena, M.T. (María Teresa)-
dc.creatorPuig, N. (Noemí)-
dc.creatorMartínez-López, J. (Joaquín)-
dc.creatorRosiñol, L. (Laura)-
dc.creatorGutierrez, N.C. (Norma C.)-
dc.creatorMartin-Ramos, M.L. (Maria Luisa)-
dc.creatorOriol, A. (Albert)-
dc.creatorTeruel, A.I. (Ana Isabel)-
dc.creatorEcheveste, M.A. (Maria Asuncion)-
dc.creatorRaquel-
dc.creatorArriba, F. (Felipe) de-
dc.creatorHernandez, M.T. (Miguel Teodoro)-
dc.creatorPalomera, L. (Luis)-
dc.creatorMartínez, R. (Rafael)-
dc.creatorMartin, A. (Alejandro)-
dc.creatorAlegre, A. (A.)-
dc.creatorRubia, J. (Javier) de la-
dc.creatorOrfao, A. (Alberto)-
dc.creatorMateos, M.V. (María Victoria)-
dc.creatorBladé, J. (Joan)-
dc.creatorSan-Miguel, J.F. (Jesús F.)-
dc.date.accessioned2018-05-03T15:19:38Z-
dc.date.available2018-05-03T15:19:38Z-
dc.date.issued2017-
dc.identifier.citationLahuerta, J.-J., Paiva, B., Vidriales, M.-B., Cordón, L., Cedena, M.-T., Puig, N., … San-Miguel, J. F. (2017). Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. Journal of Clinical Oncology, 35(25), 2900–2910. https://doi.org/10.1200/JCO.2016.69.2517es
dc.identifier.issn0732-183X-
dc.identifier.urihttps://hdl.handle.net/10171/52013-
dc.description.abstractPurpose To perform a critical analysis on the impact of depth of response in newly diagnosed multiple myeloma (MM). Patients and Methods Data were analyzed from 609 patients who were enrolled in the GEM (Grupo Español de Mieloma) 2000 and GEM2005MENOS65 studies for transplant-eligible MM and the GEM2010MAS65 clinical trial for elderly patients with MM who had minimal residual disease (MRD) assessments 9 months after study enrollment. Median follow-up of the series was 71 months. Results Achievement of complete remission (CR) in the absence of MRD negativity was not associated with prolonged progression-free survival (PFS) and overall survival (OS) compared with near-CR or partial response (median PFS, 27, 27, and 29 months, respectively; median OS, 59, 64, and 65 months, respectively). MRD-negative status was strongly associated with prolonged PFS (median, 63 months; P , .001) and OS (median not reached; P , .001) overall and in subgroups defined by prior transplantation, disease stage, and cytogenetics, with prognostic superiority of MRD negativity versus CR particularly evident in patients with high-risk cytogenetics. Accordingly, Harrell C statistics showed higher discrimination for both PFS and OS in Cox models that included MRD (as opposed to CR) for response assessment. Superior MRD-negative rates after different induction regimens anticipated prolonged PFS. Among 34 MRD-negative patients withMMand a phenotypic pattern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at diagnosis, the probability of “operational cure” was high; median PFS was 12 years, and the 10-year OS rate was 94%. Conclusion Our results demonstrate that MRD-negative status surpasses the prognostic value of CR achievement for PFS and OS across the disease spectrum, regardless of the type of treatment or patient risk group. MRD negativity should be considered as one of the most relevant end points for transplant-eligible and elderly fit patients with MM.es_ES
dc.description.sponsorshipSupported by the Centro de Investigaci ´on Biom´edica en Red – Area de Oncologia - del Instituto de Salud Carlos III (CIBERONC; CB16/12/00369; CB16/12/00400; CB16/12/00233; CB16/12/00284), formerly named as Cooperative Research Thematic Network (Grants No. RD12/0036/0058, RD12/0036/0048, RD12/0036/0046, and RD12/0036/0061) of the Red de Cancer (Cancer Network of Excellence); Instituto de Salud Carlos III/Subdirecci ´on General de Investigaci ´on Sanitaria; funded in part by the European Regional Development Fund (FIS No. 98/1239, 00/10160, 01/0089, 02/0089, 02/0905, G03/136, PI051284, PI06033906/1354, PS09/01897/01370, PI12/01761, PI12/ 02311, PI13/01469, PI14/01867, G03/136); Sara Borrell (No. CD13/00340); Asociaci ´on Española Contra el C´ancer (No. GCB120981SAN); and Federaci ´on Española de Enfermedades Raras. Also supported internationally by the Black Swan Research Initiative of the International Myeloma Foundation and the European Research Council 2015 Starting Grant (MYELOMANEXT).es_ES
dc.language.isospaes_ES
dc.relationinfo:eu-repo/grantAgreement/EC/H2020/680200/EU-
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.subjectMaterias Investigacion::Ciencias de la Salud::Hematologíaes_ES
dc.titleDepth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trialses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://www.ncbi.nlm.nih.gov/pubmed/28498784es_ES
dc.identifier.doi10.1200/JCO.2016.69.2517-

Files in This Item:
Thumbnail
File
emss-72834.pdf
Description
Size
1.85 MB
Format
Adobe PDF


Statistics and impact
0 citas en
0 citas en

Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.